ARTICLE | Clinical News
Anti-VEGF/Ang2 Nanobody: Phase I started
February 8, 2016 8:00 AM UTC
Boehringer began a dose-escalation Phase I trial to evaluate BI 836880 in patients. The trial start triggered a EUR8 million ($8.7 million) milestone payment to Ablynx from Boehringer under a 2007 dea...